JPH04257516A - Plaster for treatment of dermatosis - Google Patents

Abstract

PURPOSE:To provide a plaster for the treatment of dermatosis, having uniformly coated ointment and free from the adhesion of the ointment to a protection liner in the peeling of the liner to ensure easy application to the skin. CONSTITUTION:An ointment is uniformly applied to a substrate such as woven fabric or nonwoven fabric. The coated layer is successively laminated with a sheet layer (separation layer) having softness or extensibility higher than those of the substrate and with a protection liner such as a plastic film to obtain the objective plaster. The outside of the substrate may be covered with cloth, paper, etc., to prevent the extrusion of the ointment from a side of the substrate. The plaster is stored until use in the form sealed in an air-tight container made of aluminum adhesive film, etc.

Description

[Detailed description of the invention]

0001

[Industrial Application Field] The present invention alleviates patient pain,
This invention relates to a patch for treating skin diseases that increases the efficiency of treatment.

0002

BACKGROUND OF THE INVENTION Ointments are used in various ways as external medicines, but a patch containing an ointment for treating skin diseases has not yet been developed.

0003

[Problems to be solved by the invention] When applying ointment to the affected area, the patient complains of pain when touching the affected area with a finger, so it is difficult to use, and if the affected area is large, it is difficult to apply the ointment evenly over the entire surface. There is also the inconvenience that it takes time to do so. Furthermore, after applying the ointment, it is necessary to cover the applied surface with gauze, absorbent cotton, oiled paper, etc. to prevent it from adhering to clothing, which has caused complaints that it is time-consuming for the practitioner. Therefore, it has been desired to develop a patch to which an ointment is applied in advance.

[0004] First, an attempt was made to create a patch in which ointment was applied to a support such as non-woven fabric, and the ointment surface was protected with a plastic film (protective liner) made of polyethylene, polypropylene, etc., as in conventional poultices. It was found that there was a problem in which, when peeled off, the ointment remained attached to the protective liner and peeling occurred between the support and the ointment. After conducting various studies to solve this problem, we found that it is sufficient to interpose a sheet-like layer (referred to as a separation layer in the present invention) that is softer or more stretchable than the support between the ointment and the protective liner. The present invention has been completed.

[0005]

[Means for Solving the Problems] That is, the present invention
As shown in FIG. 1, this patch for treating skin diseases has a structure in which a support 1, an ointment layer 2, a separation layer 3, and a protective liner 4 are laminated in this order. The support used in the present invention is a woven fabric or non-woven fabric made of cotton, cellulose, staple fiber, chemical fiber, etc., or a foam sheet made of soft vinyl chloride, polyethylene, polyurethane, etc., with the primary consideration of uniform adhesion to the affected area. etc. are appropriate. In particular, woven or non-woven fabrics made of breathable cotton, cotton, cellulose, etc. are preferred. These materials can also be made to have stretchability and drapability in order to improve their adhesion to the human body.

[0006] The separation layer used in the present invention needs to have physical properties that are softer or easier to stretch than the above-mentioned support. However, its chemical properties may be the same as the support or different. These separation layers include, for example, woven or non-woven fabrics such as cotton, cellulose, staple fiber, and chemical fibers, soft vinyl chloride, polyethylene,
A foam sheet made of polyurethane or the like is used. Whether or not the separation layer is softer or more stretchable than the support can be determined by determining the bending resistance,
This can be determined by measuring and comparing the elongation rate (30% modulus) or porosity.

The methods for measuring bending resistance, elongation (30% modulus) and porosity are as follows. Measuring bending resistance: Width 2
A test piece with a length of 15 cm and a length of 15 cm was placed on the horizontal table of a cantilever type test device with a 45° slope, and after aligning the short side of the test piece with the base line of the scale, the test piece was gently moved in the direction of the slope. Determine the length of the specimen pushed out when one end (center) of the specimen touches the slope. Measurement of elongation rate (30% modulus): width 5 cm, length 20 cm
A test piece was prepared according to the JIS L1068 textile tensile test method, with a grip interval of 10 cm and a tensile speed of 30 ± 2 c.
The test piece is pulled at m/min and the load is determined when the test piece is elongated by 30%. Measurement of porosity: Place the sample on a mount of an appropriate color so that the pattern of the sample can be clearly seen, and make an enlarged copy. Next, graph paper for tracing was placed on top of this, and the area of the gap was actually measured. As is clear from the above measurement method, it can be said that the smaller the values of bending resistance and elongation rate (30% modulus) and the larger the porosity, the softer and easier it is to stretch.

By using a material that is softer and more stretchable than the support as the separation layer, when the protective liner is peeled off from the patch, peeling does not occur at the interface between the support and the ointment, and the separation layer adheres to the protective liner. Peeling occurs at the interface between the ointment and the separation layer. As the protective liner for protecting the separation layer, plastic films such as polyethylene, polypropylene, polyvinyl chloride, polyester, etc., and embossed films thereof can be used.

[0009] The ointment can be used in a conventional manner, for example, an oil-based ointment, an emulsion ointment, or a water-soluble ointment prepared according to the Japanese Pharmacopoeia, General Preparations section, Ointments. For example, a base, some emulsifiers and stabilizers are heated, melted, mixed and kept at about 75°C, and water-soluble stabilizers and emulsifiers are dissolved in water and heated to about 75°C. It is an ointment (medicinal bulk) in which the ingredients are added, stirred, cooled to an appropriate temperature, the main drug (active ingredient) is added, and the quality is equalized by stirring.

[0010] Although there are no particular restrictions on what is used as the main drug (active ingredient), lysozyme is preferred according to tests. Protein drugs such as plasmin, bromelain, epidermal growth factor (EGF), and kallikrein are also used. Other examples include sulfa drugs such as sulfizomidine and sulfadiazine, antibiotics such as kanamycin, erythromycin, chloramphenicol, and gentamicin, corticosteroids such as hydrocortisone, dexamethasone, and fluocinonide, and anti-inflammatory analgesics such as diphenhydramine and indomethacin. , vitamin preparations such as tocopherol, and the like.

[0011] The ointment may be spread and coated onto the support at room temperature or below by a conventional doctor knife method, T-die method, roll coating method, or the like. The coating thickness of the ointment is suitably 0.5 to 5 mm, but in order to fully exhibit its therapeutic effect, it is preferably 1 mm or more. In addition, in consideration of workability when applying to the human body, the edges of the patch
~4 mm may be kept without ointment. When a sheet with a large porosity is used as a support, the ointment may seep out from the openings of the sheet, so to prevent this, the outside of the support may be further covered with cloth, nonwoven fabric, paper, etc. Although the size of the patch is not particularly limited, it is preferably A6 to A3 size so that it can be used in various sizes. These patches are stored in sealed containers made of aluminum adhesive film or the like until they are used.

0012

[Example] The present invention will be explained in more detail with reference to Examples. Example 1 A nonwoven fabric with a weight of 100 g per square meter, a bending resistance of 200 mm, and an elongation rate of 0.1 kg is used as a support, and a separation layer is a nonwoven fabric with a weight of 30 g per square meter and a bending resistance of 50 mm. ,
A nonwoven fabric with an elongation rate of 0.1 kg was used. 25 on the support
Lysozyme ointment (Reflap ointment,
(manufactured by Hitachi Chemical) was spread to a width of 14 cm and a thickness of 1.5 mm using a knife doctor, and a separation layer was laminated on top of it.
Furthermore, a polyester film (25 μm) was laminated on the separation layer. Place a 1.5cm ear on one side of the ointment application area, cut it into a 10cm length, and make sure the size of the ointment area is 10x.
A skin disease treatment patch with a size of 14 cm and a support, separation layer and protective liner of 10 x 15.5 cm was prepared. The adhesion rate of the ointment to the facing (separation layer + protective liner) at the time of peeling was as good as 5%.

Example 2 A support material with bending resistance of 20 mm and elongation rate of 0.5
A nonwoven fabric having a bending resistance of 10 mm and an elongation rate of 0.01 kg was used as a separation layer. A refrap ointment that had been stored for one day at 25°C was spread on a support to a thickness of 3 mm using two rolls, a separation layer was laminated thereon, and a 25 μm polyethylene film was further placed on top of the separation layer. Laminated. At this time, in order to prevent the ointment from seeping out from the opening of the support, a nonwoven fabric weighing 100 g per square meter was further laminated on the support side. The nonwoven fabric on the support side can be used as a cover material without being removed during use. This was cut in the same manner as in Example 1,
We created a patch for treating skin diseases. The adhesion rate of ointment to the facing when this product was peeled off was as good as 1%.

Example 3 As a support, gauze with a bending resistance of 20 mm and an elongation rate of 2.0 kg was used, and as a separation layer, a gauze with a bending resistance of 20 mm and an elongation rate of 0.1k was used.
The procedure was carried out in the same manner as in Example 2, except that the nonwoven fabric of g was used.
We created a patch for treating skin diseases. The ointment adhesion rate to the facing when this product was peeled off was as good as 3%.

Example 4 A polyethylene net with a porosity of 20% was used as the support, and a polyethylene net with a porosity of 50% was used as the separation layer (bending resistance of 20 mm and elongation rate of 0.5 kg were the same for both). The same procedure as in Example 2 was carried out to prepare a patch for treating skin diseases. The ointment adhesion rate to the facing when this product was peeled off was as good as 3%.

[0016] As a comparative example support, the weight was 100 g per square meter, and the bending resistance was 2.
The same procedure as in Example 1 was carried out except that a nonwoven fabric having a length of 0 mm, an elongation rate of 0.1 kg, and a porosity of 30% was used, and the same nonwoven fabric as that used for the support was used as the separation layer. The rate of ointment adhesion to the facing when this product was peeled off was as high as 40%.

[0017]

[Effects of the Invention] Since the dosage of ointment can be easily and reliably determined by the size of the patch, it is sufficient to select and apply a patch of a predetermined size depending on the size of the affected area. Therefore, the present invention has the effect of alleviating patient pain and increasing the efficiency of treatment.

[Brief explanation of the drawing]

FIG. 1 is a sectional view showing an example of a skin disease treatment patch according to the present invention.

[Explanation of symbols]

1: Support 2: Layer of ointment 3: Separation layer 4: Protective liner

Claims (3)

[Claims] Claims: 1. A patch for treating skin diseases, comprising a support, a layer of ointment, a separation layer and a protective liner laminated in sequence. 2. The adhesive patch according to claim 1, wherein the separation layer is in the form of a sheet that is softer or more stretchable than the support. 3. The patch according to claim 1 or 2, wherein the active ingredient of the ointment is lysozyme.